Subventricular zones: new key targets for glioblastoma treatment
Creators
- 1. Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse - Oncopôle/Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse Cedex, 31059 (France)
- 2. Toulouse NeuroImaging Center, ToNIC, Université de Toulouse, INSERM, Université Paul Sabatier, Toulouse (France)
- 3. Department of Biostatistics, Institut Universitaire du Cancer de Toulouse - Oncopôle/Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse Cedex, 31059 (France)
- 4. Department of Neurosurgery, Institut Universitaire du Cancer de Toulouse - Purpan, Place du Docteur Baylac, Toulouse Cedex, 31059 (France)
- 5. Department of Nuclear Medicine, CHU Rangueil, 1 avenue du Pr Jean Poulhès TSA 50032, Toulouse Cedex, 31059 (France)
- 6. Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse - Oncopôle/Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse Cedex, 31059 (France)
- 7. INSERM U1037, Centre de Recherche contre le Cancer de Toulouse, 1 avenue Irène Joliot-Curie, Toulouse Cedex, 31059 (France)
- 8. Université Paul Sabatier, Toulouse III, 118 route de Narbonne, Toulouse, 31062 (France)
- 9. Department of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopôle/Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse Cedex, 31059 (France)
Description
We aimed to identify subventricular zone (SVZ)-related prognostic factors of survival and patterns of recurrence among patients with glioblastoma. Forty-three patients with primary diagnosed glioblastoma treated in our Cancer Center between 2006 and 2010 were identified. All patients received surgical resection, followed by temozolomide-based chemoradiation. Ipsilateral (iSVZ), contralateral (cSVZ) and bilateral (bSVZ) SVZs were retrospectively segmented and radiation dose-volume histograms were generated. Multivariate analysis using the Cox proportional hazards model was assessed to examine the relationship between prognostic factors and time to progression (TTP) or overall survival (OS). Median age was 59 years (range: 25–85). Median follow-up, OS and TTP were 22.7 months (range 7.5–69.7 months), 22.7 months (95% CI 14.5–26.2 months) and 6.4 months (95% CI 4.4–9.3 months), respectively. On univariate analysis, initial contact to SVZ was a poor prognostic factor for OS (18.7 vs 41.7 months, p = 0.014) and TTP (4.6 vs 12.9 months, p = 0.002). Patients whose bSVZ volume receiving at least 20 Gy (V20Gy) was greater than 84% had a significantly improved TTP (17.7 months vs 5.2 months, p = 0.017). This radiation dose coverage was compatible with an hippocampal sparing. On multivariate analysis, initial contact to SVZ and V20 Gy to bSVZ lesser than 84% remained poor prognostic factors for TTP (HR = 3.07, p = 0.012 and HR = 2.67, p = 0.047, respectively). Our results suggest that contact to SVZ, as well as insufficient bSVZ radiation dose coverage (V20Gy <84%), might be independent poor prognostic factors for TTP. Therefore, targeting SVZ could be of crucial interest for optimizing glioblastoma treatment.
Availability note (English)
Available from http://dx.doi.org/10.1186/s13014-017-0791-2; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397708Additional details
Identifiers
Publishing Information
- Journal Title
- Radiation Oncology (Online)
- Journal Volume
- 12
- Journal Page Range
- vp.
- ISSN
- 1748-717X
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49082375
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- GY RANGE 10-100; MULTIVARIATE ANALYSIS; PATIENTS; RADIATION DOSES; RADIATION HAZARDS; ZONES
- Descriptors DEC
- ABSORBED DOSE RANGE; DOSES; GY RANGE; HAZARDS; HEALTH HAZARDS; MATHEMATICS; RADIATION DOSE RANGES; STATISTICS
Optional Information
- Copyright
- Copyright (c) The Author(s). 2017
- Notes
- PMCID: PMC5397708; PMID: 28424082; PUBLISHER-ID: 791; OAI: oai:pubmedcentral.nih.gov:5397708